Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 8/20 | 0.36 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.33 |
| ▸ | CAMK1D | Q8IU85 | 6/20 | 0.32 |
| ▸ | RBP4 | P02753 | 1/20 | 0.31 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25817371 | 1.00 | RIPK1 (0.36) | RIPK1EIF2AK4CAMK1DRBP4SLC6A9 | |
| SCHEMBL25822030 | 0.84 | RIPK1 (0.35) | RIPK1EIF2AK4RBP4SLC6A9KDM4E | |
| SCHEMBL25822044 | 0.79 | RIPK1 (0.42) | RIPK1SLC6A9KDM4EALDH1A1HSD17B10 | |
| SCHEMBL25294414 | 0.78 | RBP4 (0.38) | RIPK1EIF2AK4CAMK1DRBP4KDM4E | |
| SCHEMBL25294415 | 0.78 | RBP4 (0.38) | RIPK1EIF2AK4CAMK1DRBP4KDM4E | |
| SCHEMBL25816759 | 0.75 | BTK (0.37) | RIPK1EIF2AK4CAMK1DRBP4KDM4E | |
| SCHEMBL25817254 | 0.75 | RIPK1 (0.44) | RIPK1CAMK1D | |
| SCHEMBL25821729 | 0.75 | RIPK1 (0.44) | RIPK1CAMK1D | |
| SCHEMBL25255972 | 0.73 | RIPK1 (0.50) | RIPK1EIF2AK4SLC6A9BTK | |
| SCHEMBL30338522 | 0.73 | RIPK1 (0.50) | RIPK1EIF2AK4SLC6A9BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | RIPK1 1/4885EIF2AK4 543/4885CAMK1D 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.